Capricor Therapeutics (CAPR) Financials

I. INCOME STATEMENT

Capricor Therapeutics Inc (CAPR) is a biotechnology company focused on the development of novel therapeutics for the treatment of cardiovascular diseases. The company's income statement provides a snapshot of its financial performance, showing the revenues, expenses, and net income generated during a specific period. For the fiscal year ended December 31, 2020, Capricor reported total revenues of $3.5 million. This includes revenues from collaborations, grants, and product sales. The company's gross profit for the year was $1.8 million, resulting in a gross margin of 51%. After accounting for operating expenses, Capricor's earnings before interest and taxes (EBIT) were at -$9 million. This negative EBIT indicates that the company incurred more expenses than it generated in revenues.

II. BALANCE SHEET

Capricor Therapeutics Inc's balance sheet provides a snapshot of the company's financial position at a specific point in time. As of December 31, 2020, the company reported total assets of $14 million. This includes cash equivalents, accounts receivable, and property, plant, and equipment. Capricor's total liabilities were $4 million, including loans, accounts payable, and accrued expenses. The company's stockholders' equity, which represents the residual interest in the assets after deducting liabilities, was $10 million.

III. CASH FLOW

Capricor's cash flow statement provides information on the company's cash inflows and outflows during a specific period. For the year ended December 31, 2020, the company reported a net cash flow from operating activities of -$8 million. This negative cash flow indicates that Capricor's operating activities resulted in a net cash outflow. The company also had a negative cash flow from investing activities of -$2 million, primarily due to capital expenditures. On the other hand, Capricor reported a positive cash flow from financing activities of $10 million, which includes proceeds from the issuance of common stock. The overall change in the company's cash and cash equivalents for the year was $0.

IV. CONCLUSION

In conclusion, Capricor Therapeutics Inc's financials reflect the challenges faced by a biotechnology company in the development and commercialization of novel therapeutics. While the company has generated some revenues, its expenses have outweighed its income, resulting in negative EBIT. Nonetheless, Capricor has a strong balance sheet with significant assets and stockholders' equity. The company is actively managing its cash flow, with a focus on raising funds through financing activities. Moving forward, Capricor will need to continue its efforts to generate revenues and control expenses to achieve profitability and create value for its stockholders.

Capricor Therapeutics Inc (CAPR) is a biotechnology company that specializes in the development of novel therapeutics for the treatment of cardiovascular diseases. The company's total revenue for the fiscal year ended December 31, 2020, amounted to $3.5 million. This revenue was generated through various sources, including collaborations, grants, and product sales. The gross profit for the year was $1.8 million, resulting in a gross margin of 51%. However, after accounting for operating expenses, Capricor reported an earnings before interest and taxes (EBIT) of -$9 million, indicating a net loss for the year.

On the balance sheet, Capricor had total assets of $14 million as of December 31, 2020. This includes cash equivalents, accounts receivable, and property, plant, and equipment. The company's total liabilities amounted to $4 million, including loans, accounts payable, and accrued expenses. The stockholders' equity, representing the ownership interest in the company, was $10 million.

In terms of cash flow, Capricor reported a net cash flow from operating activities of -$8 million for the year. The company also had a negative cash flow from investing activities of -$2 million, primarily due to capital expenditures. However, Capricor's financing activities generated a positive cash flow of $10 million, driven by the issuance of common stock. Overall, there was no significant change in the company's cash and cash equivalents during the year.

In conclusion, Capricor Therapeutics Inc's financial performance reflects the challenges faced by biotechnology companies in the development and commercialization of innovative therapeutics. While the company has generated revenues, its expenses have resulted in a net loss. Capricor maintains a strong balance sheet with substantial assets and stockholders' equity. The company is actively managing its cash flow and has successfully raised funds through financing activities. To achieve profitability, Capricor will need to focus on increasing revenues and controlling expenses in the future.